Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung CancerAlice T. Shaw, Pasi A. Jänne, Tommaso De Pas et al.|New England Journal of Medicine|2013Cited by 3.4k
Institutional implementation of clinical tumor profiling on an unselected cancer populationLynette M. Sholl, Laura E. MacConaill, T. Khanh et al.|JCI Insight|2016Cited by 447
Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring <i>MET</i> Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical ModelsLars D. Engstrom, James G. Christensen, Ruth Aranda et al.|Clinical Cancer Research|2017Cited by 147